Posted inPress Releases
Celltrion Expands Omlyclo Biosimilars Portfolio in Europe With Launch of 300 mg Dose
Celltrion has expanded its presence in Europe's biologic medicines market with the launch of Omlyclo 300 mg, an omalizumab biosimilar, adding a higher-dose option to its existing portfolio for patients…









